Dr.Barbara Bortot is currently post-doctoral researcher at the Institute for Maternal and Child health IRCCS Burlo Garofolo. She received the Bachelor degree in Molecular Biology in 2001 from the University of Trieste. She obtained the PhD in Biology and Molecular Biotechnologies in 2008 from the University of Perugia. Since 2009 she has been working at IRCCS Burlo Garofolo and is currently in charge of studying in vitro drug delivery systems based on nanotubes and nanoparticles to treat rare metabolic diseases. At present, her research activity focuses on assessing the toxicity of new anti-neoplastic systems to treat cancer cells. Furthermore, she is currently investigating in vitro the impact of treatment of several cellular models of ovarian cancer using nanoparticles loaded with cisplatin. She is coauthor of 15 publications in international journals.